Replimune Group, Inc. (NASDAQ:REPL) Executive Chairman Philip Astley-Sparke has sold a portion of his company stock, according to a recent filing with the Securities and Exchange Commission. The transaction, which occurred on May 16, 2024, involved the sale of 37,928 shares of common stock at a weighted average price of $6.47 per share, resulting in a total transaction value of approximately $245,394.
The shares sold by Astley-Sparke were reportedly to cover tax withholding obligations linked to the partial vesting of his Restricted Stock Units (RSUs). The sale was executed through a "sell to cover" provision outlined in the award agreements under which the RSUs were granted. It is important to note that this transaction does not reflect a discretionary sale by Astley-Sparke.
The reported price range for the shares was $6.46 to $6.55, with the final weighted average coming in at $6.47 per share. Following the sale, Astley-Sparke continues to hold 1,487,350 shares of Replimune Group's common stock. The company, which operates in the biotechnology sector, is known for its focus on biological products excluding diagnostic substances.
Investors and security holders of Replimune Group can request detailed information from the reporting person regarding the specific number of shares sold at each price within the stated range. This latest stock transaction provides insight into the trading activities of one of Replimune's key executives and the ongoing financial decisions within the company's leadership.
InvestingPro Insights
Replimune Group, Inc. (NASDAQ:REPL) has seen notable activity in its stock, as highlighted by the recent transaction by Executive Chairman Philip Astley-Sparke. Investors looking at the broader financial health of Replimune Group may find the following data from InvestingPro valuable in understanding the company's current market position:
- The company's market capitalization stands at $364.81 million, reflecting its valuation in the biotechnology sector.
- Replimune's Price to Earnings (P/E) ratio is currently negative at -1.81, with an adjusted P/E ratio for the last twelve months as of Q4 2024 at -1.69, indicating that the company is not currently profitable.
- The stock has experienced a significant decline over the past year, with a 1 Year Price Total Return of -69.66%, and it is trading near its 52-week low with a price percentage of the 52-week high at 23.94%.
When considering these metrics, two InvestingPro Tips stand out for Replimune Group:
- The company's stock has taken a considerable hit over the last week, with a 1 Week Price Total Return of -11.48%, reflecting recent volatility.
- Analysts do not anticipate that the company will be profitable this year, which is consistent with the negative P/E ratio and the challenges in generating positive earnings.
For investors interested in a deeper dive into Replimune's financials and stock performance, there are additional InvestingPro Tips available. These tips offer insights that could further inform investment decisions. By using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable insights. Currently, there are 7 more tips listed in InvestingPro for Replimune Group, which can be explored in detail at InvestingPro.
The recent sale by Astley-Sparke, while not a discretionary sale, does occur within a broader context where the company's financial performance and stock price have been under scrutiny. The InvestingPro data and tips provided here offer a snapshot of the company's financial health and market perception, which may be of interest to current and potential investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.